References
- Reynolds RM, Browning GG, Nawroz I, Campbell IW von Recklinghausen’s neurofibromatosis: Neurofibromatosis type 1. Lancet 2003;361:1552–1554.
- Korf BR. Malignancy in neurofibromatosis type 1. Oncologist 2000;5:477–485.
- UK myeloma forum British committee for standards in haematology. Diagnosis and management of multiple myel-oma. Br J Haematol 2001;115:522–540.
- Gregory R, Hill J. von Recklinghausen neurofibromatosis and myelomatosis. Br J Chin Pract 1990;44:725–726.
- Iagoda AV, Gasparian NV, Belotserkovskaia MI, Pavlova IB. A case of generalized plasmocytoma in a patient with Recklinghausen’s neurofibromatosis. Klin Med (Mosk) 1996; 74:66–67.
- Karwowska-Stauberowa L, Starzynska R. A case of associated multiple myeloma and Recklinghausen’s disease (neurofibro-matosis). Pol Tyg Lek 1965;20:1508–1510.
- Shannon KM, O’Connell P, Martin GA, Paderanga D, Olson K, Dinndorf P, McCormick F. Loss of the normal NF1 allele from the bone marrow of children with type lneurofibroma-tosis and malignant myeloid disorders. N Engl J Med 1994;330:597–601.
- Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003;4:557–564.
- Rebollo A, Martinez AC. Ras proteins: Recent advances and new functions. Blood 1999;94:2971–2980.
- Mangues R, Corral T, Lu S, Symmans WF, Liu L, Pellicer A. NF1 inactivation cooperates with N-ras in in vivo lymphogenesis activating Erk by a mechanism independent of its Ras-GTPase accelerating activity. Oncogene 1998;17:1705–1716.
- Harousseau JL. Management of multiple myeloma. Rev Chin Exp Haematol 2002;6:253–275.
- Rosiriol L, Blade J, Esteve J, Aymerich M, Rozman M, Montoto S, Gine E, Nadal E, Filella X, Queralt R, Carrio A, Montserrat E. Smoldering multiple myeloma: Natural history and recognition of an evolving type. Br J Haematol 2003;123:631–636.
- Santini D, Fratto ME, Vincenzi B, La Cesa A, Dianzani C, Tonini G. Bisphosphonate effects in cancer and inflammatory diseases: In vitro and in vivo modulation of cytokine activities. BioDrugs 2004;18: 269–278.
- Kondo H, Mori A, Kubota M. Maintenance with pamidronate following first line MP or VAD therapy in multiple myeloma. Leuk Lymphoma 2003;44:303–307.
- Kondo H, Mori A. Anti-tumor activity of pamidronate in human mutiple myeloma. Leuk Lymphoma 2002;43: 919–921.
- Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998;12:220–229.
- Berenson JR. New advances in the biology and treatment of myeloma bone disease. Semin Haematol 2001;38(2 suppl 3):15–20.
- Musto P. The role of bisphosphonates for treatment of bone disease in multiple myeloma. Leuk Lymphoma 1998;31: 453–456.
- Jantunen E. Bisphosphonate therapy in multiple myeloma: Past, present, future. Eur J Haematol 2002;69:257–264.